Elham Nikram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elham Nikram has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Fliss E. M. Murtagh
Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK
2 shared publications - Gemma Clarke
Academic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, UK
2 shared publications - Irene J. Higginson
Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, UK
2 shared publications - Peter May
King’s College London
2 shared publications - Sarah Mitchell
Academic Unit of Palliative Care, Leeds Institute of Health Science, Worsley Building, Clarendon Way, University of Leeds, Leeds, UK
2 shared publications - Therese Johansson
Karolinska Institutet
2 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (7) , 908-917
Specialist palliative care improves patient experience, reduces bed days and saves money: An economic modelling study of home- and hospital-based care
Background: High-quality evidence suggests that specialist palliative care reduces the odds of dying in hospital. The economic implications have not been established. Aim: To evaluate the cost-effectiveness of home- and hospital-based specialist palliative care for adults with poor prognosis in England. Design: Health-economic decision-modelling using five-state Markov cohort models with a 24-h cycle and lifetime horizon. Setting/participants: We evaluated home- and hospital-based care separately. We modelled counterfactuals using Cochrane review evidence of treatment effects on place of death and quality of life. We estimated place of death distributions, utilisation, quality-adjusted life years, and unit and intervention costs from the literature. Results: Home-based care was associated with reduced costs of £7908 per person (95% confidence interval: −18,044 to 395) and increased quality-adjusted life years by 0.035 per person (0.033 to 0.037). Hospital-based care reduced costs by £6480 per person (−11,482 to −1671) and increased quality-adjusted life years by 0.033 per person (0.031 to 0.035). We estimated that for England in 2022, specialist palliative care supported over 20,000 people to die outside of hospital, saved approximately 1.5 million hospital bed days and reduced system expenditures by £817 million. Conclusion: Specialist palliative care reduces hospital bed days, deaths in hospital and healthcare costs, as well as improving quality of life, among adults in England. A minority who might benefit currently receive specialist palliative care and needs are growing rapidly. Expanding access may yield further gains, but bridging current gaps in access also requires new approaches to reaching and meeting the needs of underserved groups.
- 4 March 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (7) , 908-917
Open AccessSpecialist palliative care improves patient experience, reduces bed days and saves money: An economic modelling study of home- and hospital-based care
Background: High-quality evidence suggests that specialist palliative care reduces the odds of dying in hospital. The economic implications have not been established. Aim: To evaluate the cost-effectiveness of home- and hospital-based specialist palliative care for adults with poor prognosis in England. Design: Health-economic decision-modelling using five-state Markov cohort models with a 24-h cycle and lifetime horizon. Setting/participants: We evaluated home- and hospital-based care separately. We modelled counterfactuals using Cochrane review evidence of treatment effects on place of death and quality of life. We estimated place of death distributions, utilisation, quality-adjusted life years, and unit and intervention costs from the literature. Results: Home-based care was associated with reduced costs of £7908 per person (95% confidence interval: −18,044 to 395) and increased quality-adjusted life years by 0.035 per person (0.033 to 0.037). Hospital-based care reduced costs by £6480 per person (−11,482 to −1671) and increased quality-adjusted life years by 0.033 per person (0.031 to 0.035). We estimated that for England in 2022, specialist palliative care supported over 20,000 people to die outside of hospital, saved approximately 1.5 million hospital bed days and reduced system expenditures by £817 million. Conclusion: Specialist palliative care reduces hospital bed days, deaths in hospital and healthcare costs, as well as improving quality of life, among adults in England. A minority who might benefit currently receive specialist palliative care and needs are growing rapidly. Expanding access may yield further gains, but bridging current gaps in access also requires new approaches to reaching and meeting the needs of underserved groups.
- Open Access
Specialist palliative care improves patient experience, reduces bed days and saves money: an economic modelling study of home- and hospital-based care
Background: High-quality evidence suggests that specialist palliative care reduces the odds of dying in hospital. The associated economic implications have not been established. Aim: To evaluate the cost-effectiveness of home- and hospital-based specialist palliative care for adults in England. Design: Health-economic decision-modelling using five-state Markov cohort models with a 24-hour cycle and lifetime horizon. Setting/participants: We evaluated home- and hospital-based care separately for adults in England with poor prognosis. We modelled treatment counterfactuals using Cochrane review evidence of specialist palliative care treatment effects on place of death and quality of life. We estimated place of death distributions, utilisation, unit costs and quality-adjusted life years, and intervention costs, from the literature. Results: Home specialist palliative care was associated with reduced costs of £7,908 per person (95% confidence interval: -18,044 to 395) and increased quality-adjusted life years by 0.035 per person (0.033 to 0.037). Hospital specialist palliative care reduced costs by £6,480 per person (-11,482 to -1,671) and increased quality-adjusted life years by 0.033 per person (0.031 to 0.035). We estimated that for England in 2022, specialist palliative care supported over 20,000 people to die outside of hospital, saved approximately 1.5million hospital bed days and reduced system expenditures by £817million. Conclusion: Specialist palliative care reduces hospital bed days, deaths in hospital and healthcare costs, as well as improving quality of life, among adults in England. A minority who might benefit currently receive specialist palliative care and needs are growing rapidly. Expanding access would likely yield further gains. Key statements: What is already known about the topic?: Specialist palliative care increases odds of dying outside hospital and improves patient quality of life, but this is a complex intervention and not all who might benefit receive this specialist care. Cost-effectiveness of specialist palliative care, and the economic implications of reduced hospital deaths, is a persistent evidence gap for research and policy. What this paper adds?: We used decision modelling, a widely-used method in health economics that has not been routinely applied in evaluating palliative care. The key strength of this approach is the capacity to combine data from different sources to estimate cost-effectiveness when there is insufficient trial data to answer the question. We found that both hospital-based specialist palliative care and home-based specialist palliative care for adults in England represent excellent value care, reducing the average cost per patient to the NHS while improving patient outcomes. Implications for practice, theory or policy: Specialist palliative care is currently accessed by less than half of people who might benefit in England. Expanding access would likely yield further cost-savings and improve outcomes for patients and families. Other countries interested in applying these methods to their own data and services can consider using our methodological templates, which we have published open access.
Open AccessSpecialist palliative care improves patient experience, reduces bed days and saves money: an economic modelling study of home- and hospital-based care
Background: High-quality evidence suggests that specialist palliative care reduces the odds of dying in hospital. The associated economic implications have not been established. Aim: To evaluate the cost-effectiveness of home- and hospital-based specialist palliative care for adults in England. Design: Health-economic decision-modelling using five-state Markov cohort models with a 24-hour cycle and lifetime horizon. Setting/participants: We evaluated home- and hospital-based care separately for adults in England with poor prognosis. We modelled treatment counterfactuals using Cochrane review evidence of specialist palliative care treatment effects on place of death and quality of life. We estimated place of death distributions, utilisation, unit costs and quality-adjusted life years, and intervention costs, from the literature. Results: Home specialist palliative care was associated with reduced costs of £7,908 per person (95% confidence interval: -18,044 to 395) and increased quality-adjusted life years by 0.035 per person (0.033 to 0.037). Hospital specialist palliative care reduced costs by £6,480 per person (-11,482 to -1,671) and increased quality-adjusted life years by 0.033 per person (0.031 to 0.035). We estimated that for England in 2022, specialist palliative care supported over 20,000 people to die outside of hospital, saved approximately 1.5million hospital bed days and reduced system expenditures by £817million. Conclusion: Specialist palliative care reduces hospital bed days, deaths in hospital and healthcare costs, as well as improving quality of life, among adults in England. A minority who might benefit currently receive specialist palliative care and needs are growing rapidly. Expanding access would likely yield further gains. Key statements: What is already known about the topic?: Specialist palliative care increases odds of dying outside hospital and improves patient quality of life, but this is a complex intervention and not all who might benefit receive this specialist care. Cost-effectiveness of specialist palliative care, and the economic implications of reduced hospital deaths, is a persistent evidence gap for research and policy. What this paper adds?: We used decision modelling, a widely-used method in health economics that has not been routinely applied in evaluating palliative care. The key strength of this approach is the capacity to combine data from different sources to estimate cost-effectiveness when there is insufficient trial data to answer the question. We found that both hospital-based specialist palliative care and home-based specialist palliative care for adults in England represent excellent value care, reducing the average cost per patient to the NHS while improving patient outcomes. Implications for practice, theory or policy: Specialist palliative care is currently accessed by less than half of people who might benefit in England. Expanding access would likely yield further cost-savings and improve outcomes for patients and families. Other countries interested in applying these methods to their own data and services can consider using our methodological templates, which we have published open access.
- Open Access
- 15 September 2023
- Published by Wiley in Journal of Public Economic Theory
- Vol. 26 (1)
A generalized Hotelling–Downs model with asymmetric candidates
We investigate an extension of the Hotelling–Downs model to the case where the preferences of the voters do not have to be single peaked. In the case where candidates only care about winning or losing, assuming that a voter elects each candidate symmetrically with equal probability when indifferent, previous works by Fisher and Ryan and by Laffond, Laslier, and Le Breton have shown that the equilibrium outcome of the model is unique. Uniqueness also holds in the case where candidates care about the strength of their majority. Our paper shows that furthermore the equilibrium is unique for small asymmetries in voter's behavior but not necessarily for large ones. In particular, if voters always vote for the incumbent rather than a newcomer when indifferent, the equilibrium policy outcome may fail to be unique. Moreover, we provide a further sufficient condition for uniqueness. Namely, suppose all voters vote for a given candidate with the same probability when indifferent. Then, if there is a Nash equilibrium in completely mixed strategies between the candidates, it is the only Nash equilibrium.
- 15 September 2023
- Published by Wiley in Journal of Public Economic Theory
- Vol. 26 (1)
Open AccessA generalized Hotelling–Downs model with asymmetric candidates
We investigate an extension of the Hotelling–Downs model to the case where the preferences of the voters do not have to be single peaked. In the case where candidates only care about winning or losing, assuming that a voter elects each candidate symmetrically with equal probability when indifferent, previous works by Fisher and Ryan and by Laffond, Laslier, and Le Breton have shown that the equilibrium outcome of the model is unique. Uniqueness also holds in the case where candidates care about the strength of their majority. Our paper shows that furthermore the equilibrium is unique for small asymmetries in voter's behavior but not necessarily for large ones. In particular, if voters always vote for the incumbent rather than a newcomer when indifferent, the equilibrium policy outcome may fail to be unique. Moreover, we provide a further sufficient condition for uniqueness. Namely, suppose all voters vote for a given candidate with the same probability when indifferent. Then, if there is a Nash equilibrium in completely mixed strategies between the candidates, it is the only Nash equilibrium.
- Open Access
- 15 February 2022
- Published by SAGE Publications in Cephalalgia
- Vol. 42 (8) , 715-721
The clinical characteristics of familial cluster headache
Background: A positive family history predisposes to the development of cluster headache. The distinct characteristics of familial cluster headache have yet to be confirmed, however, evidence suggests a younger age of onset and higher proportion of females in this subgroup. Objectives: To assess the rate and mode of inheritance of familial cluster headache in a tertiary referral centre for headache. To describe the clinical features of familial cluster headache. Methods: A retrospective study conducted between 2007 and 2017. Cluster headache was confirmed in probands and affected relatives. Differences in demographics, clinical characteristics, and response-to-treatment in familial cluster headache were delineated through multivariate analysis using a control cohort of 597 patients with sporadic cluster headache. Results: Familial cluster headache was confirmed in 48 (7.44%) patients and predominantly reflected an autosomal dominant mode of inheritance with reduced penetrance. Familial cases were more likely to report nasal blockage (OR 4.06, 95% CI; 2.600–6.494, p < 0.001) during an attack and a higher rate of concurrent short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (OR 3.76, 95% CI; 1.572–9.953, p = 0.004). Conclusion: These findings add to evidence suggesting a genetic component to cluster headache. Here, we demonstrated prominent nasal blockage, and a higher occurrence of concomitant short-lasting unilateral neuralgiform headache with conjunctival injection and tearing in this subgroup, further delineating the phenotype.
- 15 February 2022
- Published by SAGE Publications in Cephalalgia
- Vol. 42 (8) , 715-721
Open AccessThe clinical characteristics of familial cluster headache
Background: A positive family history predisposes to the development of cluster headache. The distinct characteristics of familial cluster headache have yet to be confirmed, however, evidence suggests a younger age of onset and higher proportion of females in this subgroup. Objectives: To assess the rate and mode of inheritance of familial cluster headache in a tertiary referral centre for headache. To describe the clinical features of familial cluster headache. Methods: A retrospective study conducted between 2007 and 2017. Cluster headache was confirmed in probands and affected relatives. Differences in demographics, clinical characteristics, and response-to-treatment in familial cluster headache were delineated through multivariate analysis using a control cohort of 597 patients with sporadic cluster headache. Results: Familial cluster headache was confirmed in 48 (7.44%) patients and predominantly reflected an autosomal dominant mode of inheritance with reduced penetrance. Familial cases were more likely to report nasal blockage (OR 4.06, 95% CI; 2.600–6.494, p < 0.001) during an attack and a higher rate of concurrent short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (OR 3.76, 95% CI; 1.572–9.953, p = 0.004). Conclusion: These findings add to evidence suggesting a genetic component to cluster headache. Here, we demonstrated prominent nasal blockage, and a higher occurrence of concomitant short-lasting unilateral neuralgiform headache with conjunctival injection and tearing in this subgroup, further delineating the phenotype.
- 1 May 2019
- Published by Elsevier in Value in Health
- Vol. 22, S358
PRS50 BENRALIZUMAB FOR TREATING SEVERE EOSINOPHILIC ASTHMA: NICE SINGLE TECHNOLOGY APPRAISAL
- 1 May 2019
- Published by Elsevier in Value in Health
- Vol. 22, S358
PRS50 BENRALIZUMAB FOR TREATING SEVERE EOSINOPHILIC ASTHMA: NICE SINGLE TECHNOLOGY APPRAISAL